Drug Search Results
More Filters [+]

KF-0210

Alternative Names: kf-0210, kf 0210, kf0210
Latest Update: 2024-09-24
Latest Update Note: Clinical Trial Update

Product Description

For advanced solid tumors (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04713891)

Mechanisms of Action: EP4 Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Keythera Pharmaceuticals (Australia)
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for KF-0210

Countries in Clinic: Australia, China

Active Clinical Trial Count: 2

Highest Development Phases

Phase 1: Bladder Cancer|Colorectal Cancer|Esophageal Cancer|Gastrointestinal Cancer|Lung Cancer|Oncology Solid Tumor Unspecified|Squamous Cell Carcinoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

KFCS001

P1

Completed

Esophageal Cancer|Colorectal Cancer|Gastrointestinal Cancer|Lung Cancer|Bladder Cancer|Squamous Cell Carcinoma

2022-12-08

CTR20211433

P1

Not yet recruiting

Oncology Solid Tumor Unspecified

None

Recent News Events

Date

Type

Title